Linkedin “The U.S. FDA has approved our subcutaneous immunoglobulin therapy containing immunoglobulin and hyaluronidase as a maintenance treatment option for adults with chronic inflammatory demyelinating polyneuropathy (#CIDP). Learn more:...
Linkedin “As proud innovators in #healthcare, we’re ushering in a new era of medical breakthroughs. Follow along for updates on our #clinicaltrials, research milestones, and more. For information on our current clinical trials, visit:...
Longboard pharmaceuticals: LinkedIn “We are thrilled to announce topline data from our PACIFIC Study, evaluating bexicaserin (LP352), a potentially best-in-class and highly selective, oral, novel 5-HT2C receptor superagonist for seizures associated with a broad...
In the vast and ever-evolving landscape of medical science, where innovation continually reshapes our understanding and management of various conditions, we find ourselves standing at the frontier of epilepsy research, a realm brimming with promise and potent...
